Companies

IONS · Biotech

IONIS PHARMACEUTICALS INC

SEC company filings

Reported cash

USD 296,303,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

Upcoming catalysts

Next verified event · Clinical readout window

Sefaxersen IMAgINATION data · 2027

IgAN

Phase 3

Announced Nov 9, 2026 · Announced window

Official announcement
Source wording

Program: Sefaxersen; IMAgINATION data | | •; announced 2027 data window.

Clinical readout window

REVEAL · H2 2027

Angelman syndrome

Phase 3

Announced Nov 9, 2026 · Announced window

Official announcement
Source wording

Completed enrollment in the Phase 3 REVEAL study, with data expected in the second half of 2027

Drug pipeline

85 programs · 108 verified studies

Alicaforsen

Phase

Phase3

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationCrohn's Disease

Actual study completion2002-04-27

Alicaforsen

Phase

Phase3

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationCrohn's Disease

Study completionNot provided

Alicaforsen

Phase

Phase2

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationUlcerative Colitis

Actual study completion2005-03-24

Alicaforsen

Phase

Phase2

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationUlcerative Colitis

Actual study completion2004-10-11

APOC-III-L-Rx

Phase

Phase1

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationElevated Triglycerides (TG)

Actual study completion2018-04-30

BIIB094

Phase

Phase1

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationParkinson's Disease

Actual study completion2024-08-12

Carboplatin

Phase

Phase3

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationLung Cancer

Actual study completion2002-09-09

Carboplatin

Phase

Phase1 / Phase2

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationNon-small Cell Lung Cancer

Actual study completion2013-01

daily OAD (metformin and/or sulfonylurea)

Phase

Phase2

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationType 2 Diabetes Mellitus; Obese

Actual study completion2015-02

Docetaxel

Phase

Phase1 / Phase2

Study status

Completed
View details

IONIS PHARMACEUTICALS INC

IndicationCastrate-Resistant Prostate Cancer

Actual study completion2013-12

1 / 13

40 unverified sponsor matches remain unlinked.

Verified timeline

1 records